NCT04119024 2026-03-17Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsStanford UniversityPhase 1 Recruiting18 enrolled
NCT03432741 2025-05-26Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerMayo ClinicPhase 1 Terminated17 enrolled